Personnel expenses (Details Narrative) - Veraxa Biotech A G [Member] - CHF (SFr) |
12 Months Ended | |
|---|---|---|
Dec. 31, 2025 |
Dec. 31, 2024 |
|
| Entity Information [Line Items] | ||
| Number of VSOP shares issued | 995,100 | |
| Number of shares issued | 347,452 | 140,400 |
| share based compensation expense | SFr 347,452 | SFr 140,400 |
| General and administrative expenses | SFr 14,106,551 | SFr 2,920,321 |
| X | ||||||||||
- References No definition available.
|
| X | ||||||||||
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. No definition available.
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- References Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition The number of shares issued by the entity. Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
|
| X | ||||||||||
- Details
|